Sort   by:  
 Page size 
UnknownA phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors.
Not available
S-EPMC12529303 | biostudies-literature
UnknownA phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Not available
S-EPMC6288157 | biostudies-literature
UnknownA phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors.
Not available
S-EPMC11904481 | biostudies-literature
UnknownEnrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
Not available
S-EPMC7396305 | biostudies-literature
UnknownAssociation of Post-discharge Service Types and Timing with 30-Day Readmissions, Length of Stay, and Costs.
Not available
S-EPMC8342719 | biostudies-literature
UnknownA germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Not available
S-EPMC3676425 | biostudies-literature
UnknownHabitual Intake of Dietary Advanced Glycation End Products Is Not Associated with Arterial Stiffness of the Aorta and Carotid Artery in Adults: The Maastricht Study.
Not available
S-EPMC8245866 | biostudies-literature
UnknownTRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Not available
S-EPMC8012405 | biostudies-literature
UnknownTRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
Not available
S-EPMC7124988 | biostudies-literature
UnknownClinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
Not available
S-EPMC8414363 | biostudies-literature
Sort   by:  
 Page size